Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Akero Therapeutics appoints Yuan Xu to board of directors » 08:24
04/26/21
04/26
08:24
04/26/21
08:24
AKRO

Akero Therapeutics

$29.00 /

+0.13 (+0.45%)

, LEGN

Legend Biotech

$29.01 /

+0.79 (+2.80%)

Akero Therapeutics (AKRO)…

Akero Therapeutics (AKRO) announced the appointment of Yuan Xu, Ph.D., to its board of directors as an independent director. "Dr. Xu's extensive experience in establishing and leading biopharmaceutical development and manufacturing capabilities brings a complementary perspective to our Board," said Andrew Cheng, M.D., Ph.D., president and CEO of Akero Therapeutics. "The Akero leadership team looks forward to working with Dr. Xu as we enter late-stage development of our lead NASH candidate efruxifermin." Yuan Xu, Ph.D., most recently served as a board member and CEO for Legend Biotech (LEGN).

ShowHide Related Items >><<
LEGN Legend Biotech
$29.01 /

+0.79 (+2.80%)

AKRO Akero Therapeutics
$29.00 /

+0.13 (+0.45%)

AKRO Akero Therapeutics
$29.00 /

+0.13 (+0.45%)

03/23/21 H.C. Wainwright
Akero Therapeutics price target raised to $68 from $61 at H.C. Wainwright
03/23/21 Chardan
Akero NASH data 'very exciting outcome,' says Chardan
03/17/21 Chardan
Akero Therapeutics price target raised to $81 from $79 at Chardan
02/26/21 Guggenheim
Akero Therapeutics initiated with a Buy at Guggenheim
LEGN Legend Biotech
$29.01 /

+0.79 (+2.80%)

07/01/20 JPMorgan
Legend Biotech initiated with an Overweight at JPMorgan
07/01/20 Jefferies
Legend Biotech initiated with a Buy at Jefferies
06/30/20 Morgan Stanley
Legend Biotech initiated with an Overweight at Morgan Stanley
LEGN Legend Biotech
$29.01 /

+0.79 (+2.80%)

AKRO Akero Therapeutics
$29.00 /

+0.13 (+0.45%)

  • 08
    Jul
  • 05
    Jun
AKRO Akero Therapeutics
$29.00 /

+0.13 (+0.45%)

Conference/Events
Akero Therapeutics participates in a conference call with JPMorgan » 11:16
04/13/21
04/13
11:16
04/13/21
11:16
AKRO

Akero Therapeutics

$26.88 /

-0.29 (-1.07%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Joseph holds a conference call with CEO Cheng, CSO Rolph and CDO Yale on April 13 at 1 pm hosted by JPMorgan.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$26.88 /

-0.29 (-1.07%)

AKRO Akero Therapeutics
$26.88 /

-0.29 (-1.07%)

03/23/21 H.C. Wainwright
Akero Therapeutics price target raised to $68 from $61 at H.C. Wainwright
03/23/21 Chardan
Akero NASH data 'very exciting outcome,' says Chardan
03/17/21 Chardan
Akero Therapeutics price target raised to $81 from $79 at Chardan
02/26/21 Guggenheim
Akero Therapeutics initiated with a Buy at Guggenheim
AKRO Akero Therapeutics
$26.88 /

-0.29 (-1.07%)

  • 08
    Jul
AKRO Akero Therapeutics
$26.88 /

-0.29 (-1.07%)

Over a month ago
Hot Stocks
Akero says1st patient randomized for dosing in EFX study in F2/F3 NASH patients » 08:13
03/23/21
03/23
08:13
03/23/21
08:13
AKRO

Akero Therapeutics

$34.18 /

+2.385 (+7.50%)

Akero Therapeutics…

Akero Therapeutics announced the first patient has been randomized for dosing in its Phase 2b clinical study of Efruxifermin in the treatment of patients with F2/F3 NASH. "Randomization of the first patient in our Phase 2b HARMONY study in F2/F3 patients is yet another key milestone for Akero, which builds on our recent data in cirrhotic patients (F4) and last year's data in patients with F1-F3 fibrosis," said Kitty Yale, chief development officer of Akero. "Screening and enrollment in HARMONY are ahead of schedule and we remain on track to report topline preliminary results in the second half of 2022. We are excited about the potential benefits that EFX may offer to patients with NASH, a serious metabolic disease for which there is no FDA-approved treatment option." The Phase 2b HARMONY study is a multicenter, randomized, double-blind, placebo-controlled, clinical trial in biopsy-confirmed NASH patients with fibrosis stage 2 or 3. Patients will be randomized to receive once-weekly subcutaneous dosing of 28 or 50mg EFX, or placebo. The primary endpoint for the trial is fibrosis regression at 24 weeks. Patients will continue to receive EFX or placebo after 24 weeks during a long-term follow-up period to provide additional safety data.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

03/23/21 H.C. Wainwright
Akero Therapeutics price target raised to $68 from $61 at H.C. Wainwright
03/23/21 Chardan
Akero NASH data 'very exciting outcome,' says Chardan
03/17/21 Chardan
Akero Therapeutics price target raised to $81 from $79 at Chardan
02/26/21 Guggenheim
Akero Therapeutics initiated with a Buy at Guggenheim
AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

  • 08
    Jul
AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

Recommendations
Akero Therapeutics price target raised to $68 from $61 at H.C. Wainwright » 06:20
03/23/21
03/23
06:20
03/23/21
06:20
AKRO

Akero Therapeutics

$34.18 /

+2.385 (+7.50%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Ed Arce raised the firm's price target on Akero Therapeutics to $68 from $61 and reiterates a Buy rating on the shares after the company announced results from the Cohort C of its 16-week Phase 2a BALANCED trial of efruxifermin for the treatment of adult patients with cirrhotic nonalcoholic steatohepatitis. The rapid fibrosis improvement in cirrhotic NASH patients is unprecedented, Arce tells investors in a research note. The data are "strongly suggestive" not only of direct anti-fibrotic effects, but also of a positive read-through for the HARMONY study in F2-F3 patients, says the analyst.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

03/23/21 Chardan
Akero NASH data 'very exciting outcome,' says Chardan
03/17/21 Chardan
Akero Therapeutics price target raised to $81 from $79 at Chardan
02/26/21 Guggenheim
Akero Therapeutics initiated with a Buy at Guggenheim
11/13/20 H.C. Wainwright
Akero Therapeutics price target raised to $64 from $62 at H.C. Wainwright
AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

  • 08
    Jul
AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

Recommendations
Akero NASH data 'very exciting outcome,' says Chardan » 05:38
03/23/21
03/23
05:38
03/23/21
05:38
AKRO

Akero Therapeutics

$34.18 /

+2.385 (+7.50%)

Chardan analyst Michael…

Chardan analyst Michael Morabito reiterates a Buy rating on Akero Therapeutics with an $81 price target after the company announced results from Cohort C of the BALANCED trial, a 16-week comparison of efruxifermin versus placebo in patients with compensated F4 nonalcoholic steatohepatitis. Though the trial enrolled 30 patients, only 17 volunteered for an end of study biopsy. Of the 12 patients on efruxifermin, seven exhibited a histological response while none of the five placebo patients demonstrated a histological response, Morabito tells investors in a research note. Though the early stage trial was not powered for statistical analysis, this result still represents a "very exciting outcome" as efruxifermin is now the first NASH therapeutic to have a substantial impact on cirrhotic patients, says the analyst. Morabito believes the ability to reverse fibrosis in cirrhotic patients represents a "significant milestone" in NASH therapy, but he adds that a "long road remains" for efruxifermin.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

03/17/21 Chardan
Akero Therapeutics price target raised to $81 from $79 at Chardan
02/26/21 Guggenheim
Akero Therapeutics initiated with a Buy at Guggenheim
11/13/20 H.C. Wainwright
Akero Therapeutics price target raised to $64 from $62 at H.C. Wainwright
10/16/20 H.C. Wainwright
Akero's PRIME designation an 'important recognition,' says H.C. Wainwright
AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

  • 08
    Jul
AKRO Akero Therapeutics
$34.18 /

+2.385 (+7.50%)

Hot Stocks
Akero Therapeutics histological improvements in cirrhotic NASH post cohort C » 16:08
03/22/21
03/22
16:08
03/22/21
16:08
AKRO

Akero Therapeutics

$34.20 /

+2.4 (+7.55%)

Akero Therapeutics…

Akero Therapeutics announced results of an expansion cohort of a 16-week Phase 2a clinical trial, Cohort C, evaluating efruxiferminin the treatment of adult patients with cirrhotic nonalcoholic steatohepatitis. Of the 17 confirmed compensated cirrhosis study subjects who volunteered to have end-of-treatment biopsies, 4 of 12 patients, or 33%, treated with EFX achieved a one-stage improvement in fibrosis without worsening of NASH. Another 3 of 12 EFX patients achieved NASH resolution. In total, 7 of 12 EFX patient sshowed histological improvements. None of the 5 placebo patients achieved either one-stage improvement in fibrosis without worsening of NASH, or resolution of NASH. In addition, statistically significant improvements in glycemic control and lipoprotein profile, and a trend toward weight loss, were also observed. "I believe these data are unprecedented," said Stephen Harrison, M.D., medical director of Pinnacle Clinical Research. "Today's data in cirrhotic patients, who have the highest unmet need, show clear signals of fibrosis improvement without worsening of NASH and NASH resolution, supported by compelling, statistically significant results for non-invasive fibrosis measures. These results set EFX apart."

ShowHide Related Items >><<
AKRO Akero Therapeutics
$34.20 /

+2.4 (+7.55%)

AKRO Akero Therapeutics
$34.20 /

+2.4 (+7.55%)

03/17/21 Chardan
Akero Therapeutics price target raised to $81 from $79 at Chardan
02/26/21 Guggenheim
Akero Therapeutics initiated with a Buy at Guggenheim
11/13/20 H.C. Wainwright
Akero Therapeutics price target raised to $64 from $62 at H.C. Wainwright
10/16/20 H.C. Wainwright
Akero's PRIME designation an 'important recognition,' says H.C. Wainwright
AKRO Akero Therapeutics
$34.20 /

+2.4 (+7.55%)

  • 08
    Jul
AKRO Akero Therapeutics
$34.20 /

+2.4 (+7.55%)

Recommendations
Akero Therapeutics price target raised to $81 from $79 at Chardan » 05:37
03/17/21
03/17
05:37
03/17/21
05:37
AKRO

Akero Therapeutics

$31.76 /

-1.145 (-3.48%)

Chardan analyst Michael…

Chardan analyst Michael Morabito raised the firm's price target on Akero Therapeutics to $81 from $79 and reiterates a Buy rating on the shares following the company's 2020 results. Akero announced that patient visits for Cohort C of the Phase IIa BALANCED trial concluded in February and that it expects to report preliminary results "by April 2021," Morabito tells investors in a research note. A positive trend in fibrosis improvement for the efruxifermin-treated patients would represent an "unprecedented milestone" in nonalcoholic steatohepatitis therapy, says the analyst. Morabito believes Akero is in position for an "upside move" with the Cohort C data.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$31.76 /

-1.145 (-3.48%)

AKRO Akero Therapeutics
$31.76 /

-1.145 (-3.48%)

02/26/21 Guggenheim
Akero Therapeutics initiated with a Buy at Guggenheim
11/13/20 H.C. Wainwright
Akero Therapeutics price target raised to $64 from $62 at H.C. Wainwright
10/16/20 H.C. Wainwright
Akero's PRIME designation an 'important recognition,' says H.C. Wainwright
09/10/20 Morgan Stanley
Akero Therapeutics initiated with an Overweight at Morgan Stanley
AKRO Akero Therapeutics
$31.76 /

-1.145 (-3.48%)

  • 08
    Jul
AKRO Akero Therapeutics
$31.76 /

-1.145 (-3.48%)

On The Fly
Fly Intel: Pre-market Movers » 08:58
03/16/21
03/16
08:58
03/16/21
08:58
FTCV

FinTech Acquisition Corp. V

$10.69 /

+0.19 (+1.81%)

, AZRX

AzurRx BioPharma

$1.54 /

+0.18 (+13.24%)

, ICAD

iCAD

$18.75 /

+0.11 (+0.59%)

, JBL

Jabil

$48.90 /

+0.475 (+0.98%)

, DFH

Dream Finders Homes

$26.74 /

-0.14 (-0.52%)

, DBI

Designer Brands

$15.88 /

+0.525 (+3.42%)

, CRH

CRH

$48.34 /

+0.1 (+0.21%)

, AKRO

Akero Therapeutics

$32.91 /

+0.015 (+0.05%)

, FCEL

FuelCell

$17.07 /

-1.09 (-6.00%)

, CLSK

CleanSpark

$29.40 /

-1.5 (-4.85%)

Check out this morning's…

ShowHide Related Items >><<
JBL Jabil
$48.90 /

+0.475 (+0.98%)

ICAD iCAD
$18.75 /

+0.11 (+0.59%)

FTCV FinTech Acquisition Corp. V
$10.69 /

+0.19 (+1.81%)

FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

DFH Dream Finders Homes
$26.74 /

-0.14 (-0.52%)

DBI Designer Brands
$15.88 /

+0.525 (+3.42%)

CRH CRH
$48.34 /

+0.1 (+0.21%)

CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

AZRX AzurRx BioPharma
$1.54 /

+0.18 (+13.24%)

AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

FTCV FinTech Acquisition Corp. V
$10.69 /

+0.19 (+1.81%)

AZRX AzurRx BioPharma
$1.54 /

+0.18 (+13.24%)

02/10/21 H.C. Wainwright
AzurRx BioPharma price target raised to $3.50 from $2 at H.C. Wainwright
01/06/21 Dawson James
AzurRx BioPharma downgraded to Neutral from Buy at Dawson James
ICAD iCAD
$18.75 /

+0.11 (+0.59%)

02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
02/25/21 Craig-Hallum
iCAD price target raised to $22 from $15 at Craig-Hallum
02/25/21 Lake Street
iCAD price target raised to $21 from $17 at Lake Street
JBL Jabil
$48.90 /

+0.475 (+0.98%)

12/21/20 Citi
Citi names Dell new to pick for 2021, adds to Focus List
12/18/20 RBC Capital
Jabil price target raised to $44 from $38 at RBC Capital
12/18/20 Citi
Jabil price target raised to $60 from $50 at Citi
12/18/20 JPMorgan
Flex downgraded to Neutral on valuation at JPMorgan
DFH Dream Finders Homes
$26.74 /

-0.14 (-0.52%)

02/18/21 Wedbush
Dream Finders Homes initiated with Neutral at Wedbush on valuation
02/18/21 Wedbush
Dream Finders Homes initiated with a Neutral at Wedbush
02/16/21 BTIG
Dream Finders Homes initiated with a Neutral at BTIG
02/16/21 RBC Capital
Dream Finders Homes initiated with a Sector Perform at RBC Capital
DBI Designer Brands
$15.88 /

+0.525 (+3.42%)

01/21/21 Deutsche Bank
Designer Brands price target raised to $12 from $7 at Deutsche Bank
01/08/21 CL King
Designer Brands named a top pick for 2021 at CL King
11/09/20 UBS
Designer Brands initiated with a Neutral at UBS
11/03/20 Susquehanna
Designer Brands upgraded to Positive from Neutral at Susquehanna
CRH CRH
$48.34 /

+0.1 (+0.21%)

03/10/21 JPMorgan
CRH price target raised to EUR 46 from EUR 43 at JPMorgan
03/09/21 Societe Generale
CRH price target raised to 4,000 GBp from 3,900 GBp at Societe Generale
03/08/21 Barclays
CRH price target raised to EUR 38 from EUR 35 at Barclays
03/08/21 Berenberg
CRH price target raised to EUR 38 from EUR 36 at Berenberg
AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

02/26/21 Guggenheim
Akero Therapeutics initiated with a Buy at Guggenheim
11/13/20 H.C. Wainwright
Akero Therapeutics price target raised to $64 from $62 at H.C. Wainwright
10/16/20 H.C. Wainwright
Akero's PRIME designation an 'important recognition,' says H.C. Wainwright
09/10/20 Morgan Stanley
Akero Therapeutics initiated with an Overweight at Morgan Stanley
FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

03/05/21 JPMorgan
FuelCell price target lowered to $9 from $10 at JPMorgan
01/22/21 Canaccord
FuelCell price target raised to $15 from $8.50 at Canaccord
01/14/21
Fly Intel: Top five analyst downgrades
01/14/21 JPMorgan
'Richly valued' FuelCell downgraded to Underweight at JPMorgan
CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

03/10/21 BTIG
CleanSpark initiated with a Buy at BTIG
03/10/21 BTIG
CleanSpark initiated with a Buy at BTIG
02/16/21 H.C. Wainwright
CleanSpark price target raised to $50 from $24 at H.C. Wainwright
12/11/20 H.C. Wainwright
CleanSpark price target raised to $24 from $18 at H.C. Wainwright
JBL Jabil
$48.90 /

+0.475 (+0.98%)

ICAD iCAD
$18.75 /

+0.11 (+0.59%)

FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

DFH Dream Finders Homes
$26.74 /

-0.14 (-0.52%)

DBI Designer Brands
$15.88 /

+0.525 (+3.42%)

CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

  • 16
    Mar
  • 03
    Mar
  • 21
    Jan
  • 02
    Dec
  • 07
    Oct
  • 30
    Sep
  • 08
    Jul
FTCV FinTech Acquisition Corp. V
$10.69 /

+0.19 (+1.81%)

FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

CRH CRH
$48.34 /

+0.1 (+0.21%)

CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

ICAD iCAD
$18.75 /

+0.11 (+0.59%)

FTCV FinTech Acquisition Corp. V
$10.69 /

+0.19 (+1.81%)

FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

DFH Dream Finders Homes
$26.74 /

-0.14 (-0.52%)

DBI Designer Brands
$15.88 /

+0.525 (+3.42%)

CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

AZRX AzurRx BioPharma
$1.54 /

+0.18 (+13.24%)

AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

DFH Dream Finders Homes
$26.74 /

-0.14 (-0.52%)

CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

Earnings
Akero Therapeutics reports Q4 EPS (86c), consensus (59c) » 08:03
03/16/21
03/16
08:03
03/16/21
08:03
AKRO

Akero Therapeutics

$32.91 /

+0.015 (+0.05%)

"In 2020 we reported…

"In 2020 we reported strong results from our Phase 2a BALANCED study in biopsy-confirmed NASH patients suggesting that our lead asset, efruxifermin, has the potential to be a foundational monotherapy for treatment of NASH," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "We have been particularly pleased with biopsy data that showed rapid improvements in both fibrosis and NASH resolution and look forward to reporting additional biopsy data among cirrhotic patients by April of this year."

ShowHide Related Items >><<
AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

02/26/21 Guggenheim
Akero Therapeutics initiated with a Buy at Guggenheim
11/13/20 H.C. Wainwright
Akero Therapeutics price target raised to $64 from $62 at H.C. Wainwright
10/16/20 H.C. Wainwright
Akero's PRIME designation an 'important recognition,' says H.C. Wainwright
09/10/20 Morgan Stanley
Akero Therapeutics initiated with an Overweight at Morgan Stanley
AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

  • 08
    Jul
AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

Initiation
Akero Therapeutics initiated with a Buy at Guggenheim » 07:51
02/26/21
02/26
07:51
02/26/21
07:51
AKRO

Akero Therapeutics

$29.94 /

-0.72 (-2.35%)

Guggenheim analyst Etzer…

Guggenheim analyst Etzer Darout initiated coverage of Akero Therapeutics with a Buy rating and $54 price target.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$29.94 /

-0.72 (-2.35%)

AKRO Akero Therapeutics
$29.94 /

-0.72 (-2.35%)

11/13/20 H.C. Wainwright
Akero Therapeutics price target raised to $64 from $62 at H.C. Wainwright
10/16/20 H.C. Wainwright
Akero's PRIME designation an 'important recognition,' says H.C. Wainwright
09/10/20 Morgan Stanley
Akero Therapeutics initiated with an Overweight at Morgan Stanley
08/31/20 B. Riley
NGM released 'overwhelmingly positive' NASH update, says B. Riley FBR
AKRO Akero Therapeutics
$29.94 /

-0.72 (-2.35%)

  • 08
    Jul
AKRO Akero Therapeutics
$29.94 /

-0.72 (-2.35%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.